|Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRASá…|
E Van Cutsem, CH K÷hne, I Lßng, G Folprecht, MP Nowacki, S Cascinu, ...
J Clin Oncol 29 (15), 2011-2019, 2011
|Bioresorbable airway splint created with a three-dimensional printer|
DA Zopf, SJ Hollister, ME Nelson, RG Ohye, GE Green
New England Journal of Medicine 368 (21), 2043-2045, 2013
|Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials: A study of the GISCAD (Gruppo Italiano per loá…|
E Mari, I Floriani, A Tinazzi, A Buda, M Belfiglio, M Valentini, S Cascinu, ...
Annals of Oncology 11 (7), 837-843, 2000
|Addressing the challenges of pancreatic cancer: future directions for improving outcomes|
M Hidalgo, S Cascinu, J Kleeff, R Labianca, JM L÷hr, J Neoptolemos, ...
Pancreatology 15 (1), 8-18, 2015
|Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial|
E Van Cutsem, M Nowacki, I Lang, S Cascinu, I Shchepotin, J Maurel, ...
Journal of Clinical Oncology 25 (18_suppl), 4000-4000, 2007
|PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer|
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
|Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, noná…|
TJ Price, M Peeters, TW Kim, J Li, S Cascinu, P Ruff, AS Suresh, ...
The Lancet Oncology 15 (6), 569-579, 2014
|Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial|
S Cascinu, V Catalano, L Cordella, R Labianca, P Giordani, AM Baldelli, ...
Journal of Clinical Oncology 20 (16), 3478-3483, 2002
|PD-1 blockade therapy in renal cell carcinoma: current studies and future promises|
F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ...
Cancer treatment reviews 41 (2), 114-121, 2015
|Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)|
C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ...
Annals of Oncology 18 (3), 510-517, 2007
|Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab|
A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ...
Journal of Clinical Oncology 25 (22), 3238-3245, 2007
|Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab|
M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ...
Annals of oncology 20 (2), 227-230, 2009
|Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment withá…|
M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu
Journal of clinical oncology 22 (23), 4772-4778, 2004
|Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke|
DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ...
American journal of preventive medicine 20 (2), 16-66, 2001
|Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer|
S Cascinu, MP Staccioli, G Gasparini, P Giordani, V Catalano, R Ghiselli, ...
Clinical Cancer Research 6 (7), 2803-2807, 2000
|Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.|
S Cascinu, L Cordella, E Del Ferro, M Fronzoni, G Catalano
Journal of Clinical Oncology 13 (1), 26-32, 1995
|Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.|
S Cascinu, A Fedeli, E Del Ferro, S Luzi Fedeli, G Catalano
Journal of clinical oncology 12 (5), 1058-1062, 1994
|The evolving role of microsatellite instability in colorectal cancer: a review|
F Gelsomino, M Barbolini, A Spallanzani, G Pugliese, S Cascinu
Cancer treatment reviews 51, 19-26, 2016
|Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)|
C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu, ...
British journal of cancer 101 (8), 1261-1268, 2009
|Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
S Cascinu, M Falconi, V Valentini, S Jelic
Annals of oncology 21, v55-v58, 2010